RxDoctor Payments Data

Tiana Mathieson, OD

Optometrist · Norfolk, VANPI 1144725268

Payments from drug & device makers

$1,815in general payments, 2019–2025

Across 32 payments — averaging $56.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$636
  • Bausch & Lomb Americas Inc.$480
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$258
  • Carl Zeiss Meditec USA, Inc.$200
  • Oyster Point Pharma, Inc.$117
  • Tarsus Pharmaceuticals, Inc.$109
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$1,815100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,815 in reported general payments places this provider in the 70th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$28,791
Medicare patients
180
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost39$21,313
RestasisCyclosporine11$9,922
VyzultaLatanoprostene Bunod15$5,863
LumiganBimatoprost14$4,026
Latanoprost130$1,913
Prednisolone Acetate49$1,614
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$1,488
MoxifloxacinMoxifloxacin Hcl28$963
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat29$451
Timolol Maleate40$416
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha27$322
ErythromycinErythromycin Base16$176
Brimonidine Tartrate27$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$480$5,86315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →